Novavax Inc (NVAX) — 分析摘要
Novavax Inc(NVAX)的市值为1.47十亿美元,最近一年的营收同比增长了+64.7%。净利润率为39.2%。当前市盈率为-16.7倍。
核心要点
- 营收同比变化+64.7%
- 净利润率39.2%
- 市盈率-16.7倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比,NVAX的营收增长为+64.7%,市盈率为-16.7倍。
Novavax Inc (NVAX)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -3.6x — 盈利不足以覆盖利息支出
营收较上一期下降 46.9%。
净利润由上一期盈利转为亏损。
股东权益为负,可能意味着资产负债表承压。
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
749
总部
GAITHERSBURG, MD
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$1.27
股息收益率
15.14%
股息历史
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。